Cancer Genetics (Cancer Genetics) Change In Prepaid Assets : $0.00 Mil (TTM As of Dec. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Cancer Genetics Change In Prepaid Assets?

Cancer Genetics's Change In Prepaid Assets for the quarter that ended in Dec. 2020 was $0.00 Mil. It means Cancer Genetics's Prepaid Assets stayed the same from Sep. 2020 to Dec. 2020 .

Cancer Genetics's Change In Prepaid Assets for the fiscal year that ended in Dec. 2020 was $0.00 Mil. It means Cancer Genetics's Prepaid Assets stayed the same from Dec. 2019 to Dec. 2020 .

Cancer Genetics Change In Prepaid Assets Historical Data

The historical data trend for Cancer Genetics's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Genetics Change In Prepaid Assets Chart

Cancer Genetics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Change In Prepaid Assets

Get a 7-Day Free Trial

Cancer Genetics Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Change In Prepaid Assets	Get a 7-Day Free Trial															-	-	-	-	-

Cancer Genetics Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cancer Genetics Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of Cancer Genetics's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Genetics (Cancer Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cancer Genetics Inc (NAS:CGIX) » Definitions » Change In Prepaid Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Route 17 North, 2nd Floor, Meadows Office Complex, Rutherford, NJ, USA, 07070

Website

http://www.cancergenetics.com

Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The company is focused on precision and translational medicine to drive drug discovery and novel therapies. Its subsidiary, vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. VivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.

Executives

Ralf Brandt	officer: President, Discovery Services	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael Glenn Miles	officer: Chief Financial Officer	C/O CANCER GENETICS INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Franklyn G Prendergast	director
Chaganti Raju S.k.	director	201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Edmund Cannon	director	201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Geoffrey E. Harris	director	8 HARTLEY FARMS ROAD, MORRISTOWN NJ 07960
Howard Mcleod	director	201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
John Pappajohn	director	1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
John A Roberts	officer: Chief Executive Officer	C/O CANCER GENETICS, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
William Lansing Finger	officer: EVP Precision Medicine	201 ROUTE 17N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael Brian Mccartney	officer: Chief Commercial Officer	C/O CANCER GENETICS, INC., 201 ROUTE 17 N, 2ND FLOOR, RUTHERFORD NJ 07070
Rita Shaknovich	officer: Chief Medical Officer	C/O CANCER GENETICS, INC. 201 ROUTE 17N, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas F Widmann	director	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael J. Welsh	director	UNIV. OF IOWA CARVER COLLEGE OF MEDICINE, DEPT. OF INTERNAL MEDICINE, 500 EMRB, IOWA CITY IA 52242
Igor Gitelman	officer: Chief Accounting Officer	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070